Tetracyclines are broad-spectrum bacteriostatic antibiotics that inhibit bacterial protein synthesis by binding reversibly to the 30S ribosomal subunit, blocking aminoacyl-transfer RNA (tRNA) from entering the acceptor site of the ribosome. The class has evolved from the original natural tetracyclines through semisynthetic modifications to the glycylcyclines, a structurally distinct subclass engineered specifically to overcome the two major resistance mechanisms that had severely limited the clinical utility of earlier agents.1
The tetracycline scaffold is a four-ring naphthacene carboxamide structure. Clinically active agents carry specific substituents at positions C-5, C-6, and C-7 that determine lipophilicity, oral absorption, half-life, and spectrum. All tetracyclines share the same core mechanism: they enter bacterial cells through passive diffusion across the outer membrane and through active uptake via a magnesium-chelate complex that is transported across the inner membrane by an energy-dependent system. Once inside the cell, the drug binds reversibly to the 30S ribosomal subunit at the primary binding site near the decoding center, where it blocks the binding of aminoacyl-tRNA to the ribosomal acceptor site (A site). This prevents the elongation step of protein synthesis, halting polypeptide chain elongation without directly damaging the ribosome. The effect is reversible, which is why tetracyclines are classically bacteriostatic rather than bactericidal; clearance of the drug allows ribosomal function to resume.12
Tetracyclines chelate divalent and trivalent metal cations, particularly magnesium (Mg2+), calcium (Ca2+), and aluminum (Al3+), through their beta-diketone and amide functional groups. The magnesium-tetracycline complex is the form that crosses the bacterial inner membrane via the active transport system, making metal chelation central to drug entry. However, this same chelation chemistry is responsible for two of the most clinically important properties of the class: the oral absorption interaction with polyvalent cation-containing products and the deposition of drug in calcified tissues such as bone and developing teeth.1
First-generation tetracyclines include tetracycline and oxytetracycline, the natural products isolated from Streptomyces species in the late 1940s. These agents have significant oral absorption variability, short half-lives requiring multiple daily dosing, and are substantially affected by food, dairy, and polyvalent cations. Their clinical use has been almost entirely displaced by second-generation agents with superior pharmacokinetics. Second-generation tetracyclines include doxycycline and minocycline, semisynthetic derivatives with substantially improved pharmacokinetic profiles. Doxycycline, introduced in 1967, has a half-life of approximately 18 to 22 hours supporting once-daily dosing, higher lipophilicity enabling better tissue penetration, and oral absorption that is less severely impaired by food than first-generation agents. Minocycline has a similar half-life and shares good oral bioavailability, with the added ability to penetrate the central nervous system (CNS) more effectively than doxycycline due to its greater lipophilicity and the absence of a hydroxyl group at C-6 that reduces efflux.69
Glycylcyclines represent a structurally distinct third generation, exemplified by tigecycline, the first and currently dominant member of the class in clinical practice. Tigecycline is a 9-glycylamido derivative of minocycline, with a bulky tert-butyl glycylamido substituent at the C-9 position of ring D. This modification gives tigecycline two critical properties that distinguish it from conventional tetracyclines. First, it binds to the 30S ribosomal subunit with approximately five times greater affinity than doxycycline, overcoming ribosomal protection resistance mechanisms that render classical tetracyclines ineffective. Second, the bulky C-9 substituent prevents tigecycline from being recognized as a substrate by the tetracycline-specific efflux pumps that are the most common resistance mechanism against classical tetracyclines, thereby maintaining activity against organisms that carry these pumps. The result is a broad-spectrum agent active against many multidrug-resistant (MDR) Gram-positive and Gram-negative pathogens, as well as anaerobes and atypical organisms, against which conventional tetracyclines have lost reliable activity due to resistance prevalence.34
The antimicrobial spectrum of tetracyclines evolved substantially across generations. Classical tetracyclines cover many Gram-positive and Gram-negative organisms, atypical intracellular pathogens including Chlamydia, Mycoplasma, Rickettsia, Coxiella, and Ehrlichia species, as well as spirochetes including Borrelia burgdorferi (the agent of Lyme disease). Doxycycline retains this full atypical organism spectrum and adds clinical utility against Vibrio cholerae, Yersinia pestis (plague), Brucella species, Francisella tularensis (tularemia), and Bacillus anthracis (anthrax). Tigecycline extends spectrum to carbapenem-resistant Enterobacteriaceae (CRE) and methicillin-resistant Staphylococcus aureus (MRSA) in certain contexts, but has a critical gap: it has no reliable activity against Pseudomonas aeruginosa and exhibits reduced activity against Proteus, Providencia, and Morganella species due to intrinsic efflux pump expression in these organisms.45
Tigecycline's impressive MDR coverage sometimes leads clinicians to assume it is effective against Pseudomonas aeruginosa. It is not. P. aeruginosa has constitutive expression of the MexXY-OprM efflux pump that efficiently extrudes tigecycline despite the C-9 modification that overcomes tet-specific pumps. Similarly, Proteus mirabilis, Providencia stuartii, and Morganella morganii possess intrinsic efflux that renders tigecycline unreliable for infections caused by these Enterobacteriaceae. Always check the susceptibility report before using tigecycline for Gram-negative infections.
The pharmacokinetics of tetracyclines vary considerably between generations. Doxycycline and minocycline have transformed the class by providing reliable oral bioavailability, prolonged half-lives, and tissue penetration profiles suited to treating intracellular infections. Tigecycline, by contrast, is poorly absorbed orally and is exclusively an intravenous agent, with a pharmacokinetic profile dominated by extremely large volume of distribution and biliary elimination.6
Oral bioavailability is the most clinically consequential pharmacokinetic difference between tetracycline generations. Classic tetracycline itself has oral bioavailability of approximately 60 to 80% under fasting conditions but drops substantially when taken with food, dairy, or polyvalent cation-containing products. Doxycycline achieves oral bioavailability of approximately 93% and, unlike tetracycline, this is not significantly impaired by food, making it far more reliably absorbed in routine clinical use. Minocycline has similarly high oral bioavailability approaching 95 to 100%. Tigecycline cannot be administered orally due to extensive first-pass degradation and is available only as an intravenous formulation; its low systemic bioavailability after oral administration makes an oral tigecycline preparation clinically impractical. Omadacycline, a newer aminomethylcycline approved in 2018, is notable for having both intravenous and oral formulations with good oral bioavailability, representing an advance over tigecycline in this respect.67
Chelation of polyvalent cations is the most clinically important drug interaction affecting oral tetracyclines. Calcium in dairy products and calcium supplements, magnesium and aluminum in antacids, iron in supplements and multivitamins, bismuth in antacids, and zinc in multivitamins all form insoluble chelate complexes with oral tetracyclines in the gastrointestinal lumen, dramatically reducing absorption. For tetracycline itself, concurrent antacid ingestion reduces absorption by 50 to 80%; for doxycycline, the interaction is less severe but still clinically significant, reducing absorption by approximately 20 to 40% depending on the cation concentration. The standard management recommendation is to take oral tetracyclines at least two hours before or four to six hours after any polyvalent cation-containing product. Doxycycline is the only tetracycline that can be taken with food without significant absorption impairment, but even doxycycline should be separated in time from antacids, calcium supplements, and iron preparations.8
Tissue distribution favors all tetracyclines due to their high lipophilicity and ability to concentrate in tissues, but there are clinically relevant differences between agents. Doxycycline achieves particularly high concentrations in the lungs, liver, kidneys, and prostate, supporting its clinical use in respiratory and urinary tract infections. Minocycline has superior central nervous system (CNS) penetration compared to doxycycline due to its greater lipophilicity, and has historically been used in meningococcal prophylaxis and in some CNS infections. Tetracyclines concentrate in phagocytic cells including macrophages and neutrophils, which is pharmacokinetically relevant for treating intracellular pathogens such as Rickettsia, Ehrlichia, and Chlamydophila that reside within phagolysosomes. Tigecycline has an exceptionally large volume of distribution of approximately 500 to 700 liters, reflecting extensive tissue sequestration; plasma concentrations after intravenous dosing are relatively low despite tissue levels being substantially higher, which has implications for infections where serum drug concentrations matter (such as bacteremia).6
Elimination pathways differ significantly between agents. Doxycycline is eliminated primarily through the gastrointestinal tract via biliary and intestinal secretion, with approximately 30 to 40% appearing in feces as inactive chelate complexes and the remainder undergoing renal excretion. A key clinical advantage of doxycycline is that its elimination is not significantly altered by renal impairment; unlike tetracycline, which accumulates dangerously in patients with renal failure because it is predominantly renally excreted, doxycycline can be used at standard doses in patients with advanced chronic kidney disease without dose adjustment. Minocycline is also hepatically metabolized and does not require dose adjustment for renal impairment. Tigecycline is eliminated predominantly via biliary and fecal excretion (approximately 59% of the dose) with renal elimination accounting for approximately 33%; no dose adjustment is required for renal impairment or mild-to-moderate hepatic impairment, but the dose should be reduced in severe hepatic impairment (Child-Pugh class C).6
Drug interactions beyond polyvalent cation chelation include pharmacodynamic antagonism with penicillins and other bactericidal agents. Because tetracyclines inhibit protein synthesis and halt bacterial growth, they reduce the ability of bactericidal cell-wall-active agents (penicillins, cephalosporins, vancomycin) to kill bacteria, since these agents require active bacterial growth and cell wall synthesis to exert their lethal effects. This antagonism is clinically most relevant in infections requiring bactericidal therapy, such as bacterial meningitis and infective endocarditis, where tetracyclines should not be combined with or substituted for bactericidal antibiotics. Tetracyclines also reduce the efficacy of oral contraceptives by altering gut flora that participate in enterohepatic recirculation of ethinyl estradiol, though the clinical magnitude of this interaction is debated and considered low in more recent analyses. Rifampin (rifampicin) induces cytochrome P450 (CYP) enzymes and reduces doxycycline plasma concentrations by approximately 50% through increased hepatic metabolism; patients on rifampin-containing regimens for tuberculosis or other indications who require doxycycline may need dose adjustment or an alternative agent.11
This distinction is one of the most clinically important within the tetracycline class. Tetracycline accumulates in renal failure and exacerbates azotemia through an anti-anabolic effect on protein metabolism, promoting nitrogen retention. It is contraindicated in significant renal impairment. Doxycycline, by contrast, is primarily eliminated via biliary and intestinal routes and does not accumulate in renal failure; it can be prescribed at standard doses in patients on dialysis or with advanced chronic kidney disease without dose adjustment. When a tetracycline is clinically indicated in a patient with renal impairment, doxycycline is the agent of choice.
The tetracycline adverse effect profile spans common and largely manageable gastrointestinal effects to serious toxicities with irreversible consequences, particularly the deposition of drug in developing calcified tissues that makes the class contraindicated in pregnancy and in children under age eight. Understanding the mechanistic basis of each toxicity and the specific agent most responsible is essential for safe prescribing across the class.10
Gastrointestinal adverse effects are the most common reason for tetracycline and doxycycline discontinuation and result from direct irritation of the gastrointestinal mucosa as well as disruption of the normal commensal microbiome. Nausea, vomiting, epigastric discomfort, and diarrhea occur in a dose-dependent fashion and are more prominent with oral tetracycline than with doxycycline. Esophageal ulceration is a serious and preventable complication that occurs when a tetracycline capsule or tablet is taken with insufficient water and remains in contact with the esophageal mucosa, particularly if the patient lies down shortly after ingestion. Doxycycline monohydrate capsules are more commonly associated with esophageal ulceration than hyclate formulations because of their acidic pH at the site of dissolution. Patients should be instructed to take all oral tetracyclines with a full glass of water while sitting upright and to remain upright for at least 30 minutes after dosing. Superinfection with Clostridioides difficile (formerly Clostridium difficile) can occur with any broad-spectrum antibiotic, though tetracyclines carry lower risk than fluoroquinolones or clindamycin for this complication.1011
Photosensitivity reactions are a class effect of tetracyclines and result from drug accumulation in skin followed by ultraviolet (UV) light-induced generation of reactive oxygen species that cause phototoxic tissue damage. The reaction resembles an exaggerated sunburn occurring in sun-exposed areas and can occur after relatively brief sun exposure in susceptible individuals. Demeclocycline carries the highest risk of photosensitivity within the older tetracyclines; doxycycline has significant photosensitivity risk and patients should be counseled to apply broad-spectrum sunscreen, wear protective clothing, and avoid prolonged direct sun exposure during treatment. Minocycline has lower photosensitivity risk than doxycycline. Patients taking doxycycline for extended periods, such as those using it for malaria prophylaxis in tropical climates or for chronic inflammatory skin conditions, require particularly thorough sun protection counseling. The reaction resolves after drug discontinuation but can result in post-inflammatory hyperpigmentation that persists for weeks to months.1011
Deposition in calcified tissues is the most clinically consequential class-wide toxicity of tetracyclines and is the basis for their absolute contraindication in pregnancy and in children under eight years of age. Tetracyclines chelate calcium ions and are incorporated into the calcium-phosphate matrix of bone and developing tooth enamel during periods of active calcification. In developing teeth, this produces permanent yellow-brown discoloration and hypoplasia of the enamel, primarily affecting teeth forming during drug exposure in the second and third trimesters of pregnancy and in the first eight years of postnatal life. In bone, the drug deposits at sites of active ossification and produces a fluorescent yellow band visible on histological sections; while this bone deposition is generally reversible and does not cause permanent structural bone damage in adults, it raises concern for growth retardation in young children. The contraindication in pregnancy also reflects risks of hepatotoxicity in the mother and dental/bone effects in the fetus. All tetracyclines except tigecycline carry this contraindication, and even tigecycline should be avoided in pregnancy based on its structural relatedness to the class.1112
Hepatotoxicity is a dose-related and historically significant tetracycline toxicity that presented most dramatically with high-dose intravenous tetracycline, which is no longer used clinically. Pregnant women receiving high-dose intravenous tetracycline developed severe microvesicular steatosis with liver failure, which was frequently fatal. At standard oral doses used today, hepatotoxicity is rare but can occur, particularly with pre-existing liver disease. Tetracyclines inhibit mitochondrial protein synthesis through their nonselective ribosomal binding and impair beta-oxidation of fatty acids in hepatic mitochondria, producing the microvesicular fat pattern rather than macrovesicular steatosis typical of alcoholic liver disease. Tigecycline has been associated with acute pancreatitis in postmarketing reports, a specific adverse effect not shared by conventional tetracyclines, occurring at a rate of approximately 1 to 2% in some series.10
Fanconi syndrome from degraded tetracycline is a historically important toxicity with direct implications for drug storage and dispensing practice. Outdated or improperly stored tetracycline undergoes epimerization and degradation to form 4-epitetracycline and anhydrotetracycline, toxic metabolites that cause proximal renal tubular dysfunction manifesting as the Fanconi syndrome, characterized by glycosuria without hyperglycemia, aminoaciduria, phosphaturia, bicarbonaturia, and renal tubular acidosis. The syndrome was first described in patients who took tetracycline from bottles past their expiration date stored in warm conditions. Doxycycline is more chemically stable than tetracycline and is not associated with Fanconi syndrome from degradation products. The practical clinical lesson is that tetracycline products must be discarded after expiration and stored appropriately; the question has declined in clinical relevance as tetracycline use has largely been supplanted by doxycycline.1
Vestibular toxicity is a specific adverse effect of minocycline, occurring in approximately 7 to 90% of patients in some studies and manifesting as dizziness, vertigo, ataxia, and nausea within the first few days of treatment. The mechanism is incompletely understood but appears related to minocycline accumulation in the labyrinthine fluid; unlike aminoglycoside-associated vestibular toxicity, minocycline vestibular effects are fully reversible upon drug discontinuation. Because of this effect, minocycline is generally less tolerated than doxycycline for systemic indications and has largely been displaced by doxycycline in most clinical settings where either agent would be appropriate. Women and lower body weight patients appear to be at higher risk, possibly because of higher plasma concentrations at standard weight-based dosing. Doxycycline does not cause vestibular toxicity.11
Tigecycline-specific adverse effects include a substantially higher rate of nausea and vomiting than conventional tetracyclines, occurring in approximately 20 to 35% of patients at standard dosing, compared to approximately 5 to 10% with doxycycline. The nausea is thought to result from tigecycline's effect on the chemoreceptor trigger zone and gastrointestinal motility; it can be managed with antiemetic premedication and slower infusion rates but remains the most common reason for tigecycline discontinuation. A Food and Drug Administration (FDA) safety communication issued in 2010 noted that clinical trial data showed higher all-cause mortality in tigecycline-treated patients compared to comparator antibiotics across multiple indications, possibly due to lower cure rates in bacteremic patients (where tigecycline's low plasma concentrations may be inadequate) rather than direct drug toxicity. This safety signal resulted in a label warning and has influenced guideline recommendations to avoid tigecycline monotherapy for bacteremia and to use it cautiously in hospital-acquired pneumonia where mortality data were least favorable.13
No tetracycline should be used in pregnant women or in children under age eight except in life-threatening circumstances where no effective alternative exists. This applies to doxycycline, minocycline, and tigecycline equally. The one notable exception recognized by the CDC and the American Academy of Pediatrics is the use of doxycycline in children of any age for suspected Rocky Mountain spotted fever, where the mortality risk of inadequately treated rickettsial disease outweighs the short-course dental risk. A single short course of doxycycline for suspected rickettsial disease in a child under eight is an accepted exception; the permanent dental discoloration risk from prolonged courses or repeat courses is where the contraindication is most absolute.
Doxycycline has become the dominant tetracycline in clinical practice, combining broad spectrum, excellent oral bioavailability, once-daily dosing, safety in renal impairment, and activity against the widest range of medically important intracellular and vector-borne pathogens. Tigecycline occupies a different clinical niche as an intravenous reserve agent for polymicrobial and multidrug-resistant infections. Understanding resistance mechanisms explains both the limitations of conventional tetracyclines and why glycylcyclines were specifically engineered to overcome them.5
Doxycycline indications span an exceptionally diverse range of infections, reflecting the drug's activity against intracellular, atypical, and vector-borne pathogens that resist many other antibiotic classes. In infectious disease, doxycycline is the drug of choice for rickettsial infections including Rocky Mountain spotted fever (Rickettsia rickettsii), epidemic typhus (Rickettsia prowazekii), and ehrlichiosis and anaplasmosis caused by Ehrlichia and Anaplasma species; early diagnosis and prompt initiation of doxycycline is life-saving in these rapidly progressive infections. Doxycycline is first-line for Lyme disease in adults (including Lyme arthritis and uncomplicated early Lyme carditis), for Chlamydia trachomatis and Chlamydophila psittaci infections, and for nongonococcal urethritis caused by Mycoplasma genitalium and Ureaplasma urealyticum.14 It is the preferred agent for Brucella infections (typically combined with rifampin for synergy), Coxiella burnetii (Q fever), Vibrio cholerae (cholera), and for prophylaxis and treatment of anthrax. In community-acquired pneumonia (CAP), doxycycline is a first-line alternative agent for outpatient management in patients without comorbidities, covering typical organisms and atypicals. Doxycycline is widely used for acne vulgaris (at sub-antimicrobial doses targeting its anti-inflammatory properties), for rosacea, and for periodontal disease management.10
Malaria prophylaxis and treatment represent a major global indication for doxycycline. Doxycycline is recommended by the Centers for Disease Control and Prevention (CDC) for malaria prophylaxis in areas with chloroquine-resistant Plasmodium falciparum, taken once daily beginning one to two days before travel, continuing throughout the stay, and for four weeks after returning. The antimalarial mechanism is distinct from its antibacterial mechanism of action: doxycycline disrupts the protein synthesis of the Plasmodium apicoplast, a chloroplast-derived organelle essential for parasite lipid and isoprenoid synthesis, providing slow-onset antiparasitic activity that is complemented by faster-acting blood schizontocides. For this reason, doxycycline must not be used as monotherapy for acute malaria treatment but is used in combination with quinine or artesunate for multidrug-resistant falciparum malaria treatment. Photosensitivity counseling is essential for travelers using doxycycline prophylaxis in tropical environments.10
Tigecycline indications are intentionally narrow and reflect both its unique spectrum and its limitations. Tigecycline is approved for complicated skin and soft tissue infections (cSSTI), complicated intra-abdominal infections (cIAI), and community-acquired pneumonia. In practice, its most valuable clinical role is in polymicrobial infections and in infections caused by multidrug-resistant (MDR) organisms for which few alternatives exist, including carbapenem-resistant Enterobacteriaceae (CRE), methicillin-resistant Staphylococcus aureus (MRSA) in non-bacteremic contexts, vancomycin-resistant Enterococcus (VRE), and extended-spectrum beta-lactamase (ESBL)-producing organisms resistant to most beta-lactams. Tigecycline should not be used as monotherapy for bacteremic patients given its pharmacokinetic limitations (low plasma concentrations relative to tissue concentrations), and it should not be relied upon for Pseudomonas aeruginosa coverage. Combination therapy with another active agent is often employed in serious MDR infections to prevent resistance emergence and improve outcomes.413
The three major mechanisms of tetracycline resistance are energy-dependent efflux pumps, ribosomal protection proteins, and enzymatic inactivation. Efflux is the most widespread resistance mechanism and is mediated by a large family of membrane transport proteins, encoded predominantly by tet genes (tetracycline resistance genes) on plasmids and transposons. The major efflux determinants in Gram-negative bacteria include tet(A), tet(B), tet(C), and tet(E), which encode proton-antiport membrane proteins that exchange a proton for a magnesium-tetracycline chelate complex, actively exporting drug against its concentration gradient. Gram-positive efflux pumps include tet(K) and tet(L). These efflux pumps are highly effective at reducing intracellular tetracycline and doxycycline concentrations to sub-inhibitory levels. Tigecycline evades these classical tet efflux pumps because its bulky C-9 substituent prevents recognition by the pump substrate-binding pocket, which is the primary structural basis for its sustained activity against tetracycline-resistant organisms.1516
Ribosomal protection proteins are the second major resistance mechanism and confer resistance by a mechanistically distinct mechanism from efflux. These proteins, encoded by tet(M), tet(O), tet(Q), and related genes, are GTPase proteins with structural homology to elongation factor G (EF-G). They bind to the ribosome and induce conformational changes in the 30S subunit that dislodge the tetracycline from its binding site on the ribosome, thereby restoring ribosomal function in the presence of drug. Unlike efflux pumps, ribosomal protection proteins can confer resistance even when intracellular drug concentrations are high. They are widespread in both Gram-positive and Gram-negative bacteria and are particularly prevalent in streptococci, enterococci, and Bacteroides species. Tigecycline overcomes ribosomal protection resistance because its increased ribosomal binding affinity allows it to successfully compete with and displace ribosomal protection proteins from the ribosomal binding site; the structural basis for this is the five-fold higher affinity of tigecycline for the ribosomal A site compared to tetracycline.1516
Enzymatic inactivation of tetracyclines, while less prevalent than efflux or ribosomal protection, has been described through two mechanisms. The tet(X) gene encodes a flavoprotein monoxygenase that hydroxylates tetracyclines at the C-11a position, inactivating them. Originally identified in Bacteroides and later found in other Gram-negatives, tet(X) and its variants can in principle inactivate tigecycline, representing an emerging threat to glycylcycline utility; tet(X3) and tet(X4) variants capable of conferring high-level tigecycline resistance have been reported on mobile plasmids in clinical Enterobacteriaceae isolates, raising concern for horizontal spread. The second enzymatic mechanism involves ADP-ribosylation, encoded by tet(ADP), described in some actinomycetes. Both enzymatic mechanisms are currently less clinically prevalent than efflux and ribosomal protection but represent potential future challenges to glycylcycline utility if they achieve wider horizontal dissemination.16
Rocky Mountain spotted fever caused by Rickettsia rickettsii carries a case fatality rate exceeding 20% in untreated patients and can progress from fever and rash to multi-organ failure within days. Doxycycline is the treatment of choice at all ages, including children under eight, because the risk of death from untreated or inadequately treated rickettsial disease vastly outweighs the risk of dental discoloration from a single short course. The American Academy of Pediatrics and the CDC both explicitly state that concern about dental effects should not delay doxycycline initiation in a child with suspected Rocky Mountain spotted fever. Chloramphenicol, the historical alternative for children, has substantially worse outcomes in rickettsial infections than doxycycline and is no longer preferred. Treat first; do not wait for diagnostic confirmation in a clinically compatible presentation.
Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev. 2001;65(2):232–260.
doi:10.1128/MMBR.65.2.232-260.2001Pioletti M, Schlunzen F, Harms J, et al. Crystal structures of complexes of the small ribosomal subunit with tetracycline, edeine and IF3. EMBO J. 2001;20(8):1829–1839.
doi:10.1093/emboj/20.8.1829Sum PE, Petersen P. Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936. Bioorg Med Chem Lett. 1999;9(10):1459–1462.
doi:10.1016/S0960-894X(99)00216-4Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother. 1999;43(4):738–744.
doi:10.1128/AAC.43.4.738Zhanel GG, Homenuik K, Nichol K, et al. The glycylcyclines: a comparative review with the tetracyclines. Drugs. 2004;64(1):63–88.
doi:10.2165/00003495-200464010-00005Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother. 2006;58(2):256–265.
doi:10.1093/jac/dkl224Stets R, Popescu M, Gonong JR, et al. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med. 2019;380(6):517–527.
doi:10.1056/NEJMoa1800201Neuvonen PJ. Interactions with the absorption of tetracyclines. Drugs. 1976;11(1):45–54.
doi:10.2165/00003495-197611010-00004Cunha BA. Minocycline versus doxycycline in the treatment of Lyme neuroborreliosis. Clin Infect Dis. 2000;30(1):237–238.
doi:10.1086/313604Smith K, Leyden JJ. Safety of doxycycline and minocycline: a systematic review. Clin Ther. 2005;27(9):1329–1342.
doi:10.1016/j.clinthera.2005.09.005Moffatt MF, Kaplan EL. Tetracyclines. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 8th ed. Philadelphia: Elsevier Churchill Livingstone; 2015:322–338.
Freinkel RK, Fiedler-Weiss VC. In vivo effects of tetracycline on bone mineral in the rat. J Invest Dermatol. 1965;45(2):62–65.
FDA Drug Safety Communication. FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new boxed warning. US Food and Drug Administration; September 27, 2013. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-increased-risk-death-iv-antibacterial-tygacil-tigecycline
Biggs HM, Behravesh CB, Bradley KK, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever and other spotted fever group rickettsioses, ehrlichioses, and anaplasmosis — United States. MMWR Recomm Rep. 2016;65(2):1–44.
doi:10.15585/mmwr.rr6502a1Roberts MC. Tetracycline resistance determinants: mechanisms of action, regulation of expression, genetic mobility, and distribution. FEMS Microbiol Rev. 1996;19(1):1–24.
doi:10.1111/j.1574-6976.1996.tb00251.xConnell SR, Tracz DM, Nierhaus KH, Taylor DE. Ribosomal protection proteins and their mechanism of tetracycline resistance. Antimicrob Agents Chemother. 2003;47(12):3675–3681.
doi:10.1128/AAC.47.12.3675-3681.2003